Abstract:As one of the central tasks of modern medicinal chemistry, scaffold hopping is expected to lead to the discovery of structural novel biological active compounds and broaden the chemical space of known active compounds. Here, we report the computational bioactivity fingerprint (CBFP) for easier scaffold hopping, where the predicted activities in multiple quantitative structure–activity relationship models are integrated to characterize the biological space of a molecule. In retrospective benchmarks, the CBFP representation shows outstanding scaffold hopping potential relative to other chemical descriptors. In the prospective validation for the discovery of novel inhibitors of poly [ADP-ribose] polymerase 1, 35 predicted compounds with diverse structures are tested, 25 of which show detectable growth-inhibitory activity; beyond this, the most potent (compound 6) has an IC<sub>50</sub> of 0.263 nM. These results support the use of CBFP representation as the bioactivity proxy of molecules to explore uncharted chemical space and discover novel compounds.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00234?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00234</a>.AMRR results for different screening datasets (Table S1 and Figure S1); PARP-1 inhibitors approved by FDA (Table S2); reverse target fishing of compound 6 and olaparib (Tables S3 and S4); information of the query data set (Table S5); the threshold of CBFP representation (Figure S2); workflow for CBFP construction (Figure S3) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00234/suppl_file/jm1c00234_si_001.pdf">PDF</a>).Molecular formula strings of all the compounds tested and associated biochemical data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00234/suppl_file/jm1c00234_si_002.xlsx">XLSX</a>).Information on the QSAR models of CBFP representation (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00234/suppl_file/jm1c00234_si_003.csv">CSV</a>).This article has not yet been cited by other publications.

Computational discovery of picomolar Q(o) site inhibitors of cytochrome bc1 complex.

Fragment-based Drug Discovery and Molecular Docking in Drug Design.

Crystallographic studies of quinol oxidation site inhibitors: a modified classification of inhibitors for the cytochrome bc(1) complex

Molecular Docking Study of the Cytochrome BC1 Complexed with Inhibitors

Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor

A Potent and Selective Inhibitor for the UBLCP1 Proteasome Phosphatase.

Nonoxidizable ubiquinol derivatives that are suitable for the study of the ubiquinol oxidation site in the cytochrome bc1 complex.

HLA class I and class II antigen expression on squamous cell carcinoma of the head and neck.

Identification of small‐molecule binding sites of a ubiquitin‐conjugating enzyme‐UBE2T through fragment‐based screening

Cryo-EM Structures Reveal the Unique Binding Modes of Metyltetraprole in Yeast and Porcine Cytochrome bc 1 Complex Enabling Rational Design of Inhibitors

Methadone hydrochloride to prevent impulsive behavior in mental retardation: a case report.

Fragment-Based Covalent Ligand Screening Enables Rapid Discovery of Inhibitors for the RBR E3 Ubiquitin Ligase HOIP

Identification of Novel Tyrosinase Inhibitors with Nanomolar Potency Using Virtual Screening Approaches

Structure based identification and biological evaluation of novel and potent inhibitors of PCAF catalytic domain

Computational Strategy for Bound State Structure Prediction in Structure-Based Virtual Screening: A Case Study of Protein Tyrosine Phosphatase Receptor Type O Inhibitors

Identification of FtsZ Interdomain Cleft Effectors Based on Pharmacophore Search and Molecular Docking

Identification of a novel mitochondrial interacting protein of C1QBP using subcellular fractionation coupled with CoIP-MS.

Virtual Screening Inhibitors of Ubiquitin‐specific Protease 7 combining Pharmacophore Modeling and Molecular Docking

Computational Bioactivity Fingerprint Similarities To Navigate the Discovery of Novel Scaffolds

Structure-based Virtual Screening of Novel USP5 Inhibitors Targeting the Zinc Finger Ubiquitin-Binding Domain

Application of Fragment-Based Drug Discovery to Versatile Targets